BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets

Seeking Alpha03:00

Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will

Simply Wall StJun 28 19:40

Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts

6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates th

BenzingaJun 27 21:00

Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $53

Stifel analyst Paul Matteis maintains $Ionis Pharmaceuticals(IONS.US)$ with a hold rating, and adjusts the target price from $50 to $53.According to TipRanks data, the analyst has a success rate of 46

Futu NewsJun 27 20:31 · Ratings

Ionis Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 10.46% Stifel $50 → $53 Maintains Hold 06/14/2024 — Bernstein Upgrades Underperform → Market P

BenzingaJun 27 20:19

Express News | Ionis Pharmaceuticals Inc : Stifel Raises Target Price to $53 From $50

BreakingsJun 27 19:21